Clinical trials: DFS, active
DFS
A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive
A prospective, multicenter clinical study designed to explore the efficacy of adaptive therapy based on MRD status in patients with stage II-III non-small cell lung cancer(NSCLC) after treatment.
- Trial name
- NCT06524518
- Testing
- Chemotherapy combined with immunization
- Where
- China
- Volunteers
- 213 people
- Sponsor
- Xuanwu Hospital, Beijing
Adjuvant Chemotherapy
Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.
- Trial name
- NCT06389552
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- HK inno.N Corporation
Neuroendocrine Carcinoma, Digestive Cancer
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas
NEONEC is a single-phase, phase II study evaluating the efficacy of the 12-month neoadjuvant chemotherapy in patients with locally differentiated digestive NEC.
- Trial name
- NEONEC (NCT04268121)
- Testing
- Neoadjuvant treatment, Adjuvant treatment
- Where
- 14 sites in France
- Volunteers
- 78 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's…
- Conditions
- Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model, Recurrent Renal Cell Cancer
- Trial name
- NCT06088134
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Mingzhao Xiao
Gastric Cancer
Randomized Phase II Trial Evaluating DFS in The Absence of an Adjuvant Component of Perioperative Chemotherapy in Patients With Gastric Cancer
This single-center, open-label, randomized phase II trial (JAGC-1) will evaluate whether adjuvant chemotherapy can be safely omitted in patients with stage IB-III gastric cancer (cT2-4a and/or N+) who have achieved a pathological…
- Trial name
- JAGC1 (NCT06942663)
- Testing
- Surveillance, Adjuvant Chemotherapy
- Volunteers
- 228 people
- Sponsor
- Nizhny Novgorod Regional Clinical Oncology Center
Head and Neck Mucosal Melanomas
Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma
The main objective will be to estimate the disease free survival (DFS) of patients with resectable head and neck mucosal melanomas treated by neo-adjuvant anti-PD1 (in combination or not with lenvatinib) followed by surgery…
- Trial name
- IMMUQ (NCT03313206)
- Testing
- Pembrolizumab, Surgery, IMRT
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Pancreatic Head Cancer, Pancreatic Ductal Adenocarcinoma
Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer
Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to high recurrence rates after standard pancreaticoduodenectomy (PD).
- Trial name
- TMpE (NCT07232810)
- Testing
- Total Mesopancreas Excision (TMpE)
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Minia University
Diabetic Foot, Diabetes Mellitus
Early Percutaneous Transluminal Angioplasty in Diabetic Foot Syndrome (PTA-DFS)
The planned study is a Randomized Controlled Monocentric Trial, which will provide evidence on whether early angiography in percutaneous transluminal angioplasty (PTA) readiness ("immediate" treatment, within 48h) has advantages…
- Conditions
- Diabetic Foot, Diabetes Mellitus, Peripheral Arterial Disease, Diabetic Neuropathies
- Trial name
- PTA-DFS (NCT06124586)
- Testing
- Percutaneous transluminal angioplasty
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Colorectal Cancer Stage III
The Prognosis Effect of Indocyanine Green (ICG) Fluorescence Guided Surgery on Disease-free Survival (DFS) of Stage III Colorectal Cancer
Previous studies of Indocyanine green (ICG) in colorectal surgery have focused on lymphatic mapping, lymph node detection, and the number of harvested lymph nodes.
- Trial name
- NCT06583564
- Testing
- ICG lymphangiography procedure
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Shanghai Tong Ren Hospital
Non-muscle-invasive Bladder Cancer
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer
- Trial name
- POTOMAC (NCT03528694)
- Testing
- Durvalumab (MEDI4736), Bacillus Calmette-Guerin (BCG)
- Where
- 120 sites in Australia, Austria and 10 more
- Volunteers
- 1,018 people
- Sponsor
- AstraZeneca
Duodenal, Gastrointestinal Stromal Tumors
Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST
Gastrointestinal stromal tumour (GIST) is the most common mesenchymal neoplasm of the digestive tract, originating from the interstitial cells of Cajal.
- Trial name
- NCT07837271
- Where
- 2 sites in China
- Volunteers
- 288 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis
Clinical Study on the Effect of Removal of Porphyromonas Gingivalis on Prognosis of Esophageal Cancer After Radical Surgery
Esophagectomy is an important means of radical treatment of esophageal cancer, but due to local recurrence and metastasis, the 5-year survival rate of patients with esophageal cancer is only 20-30%.
- Trial name
- NCT06418945
- Testing
- Tinidazole oral microneedle patch
- Volunteers
- 500 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology